| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Histone H31t, H3/t, H3t, H3/g, HIST3H3, H3FT |
| Entrez GeneID | 8290 |
| WB Predicted band size | 15.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This HIST3H3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 50-78 amino acids from the Central region of human HIST3H3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于HIST3H3抗体的3篇参考文献及其摘要概述：
---
1. **文献名称**：*H3K27M mutation in histone H3.3 defines pediatric gliomas with distinct growth characteristics and specific structural abnormalities*
**作者**：Schwartzentruber, J. et al.
**摘要**：该研究首次在儿童弥漫性中线胶质瘤中发现H3F3A基因(编码H3.3组蛋白)的H3K27M突变，并开发了特异性抗体用于检测此突变。研究表明，该抗体可有效区分肿瘤亚型，为诊断和预后提供依据。
2. **文献名称**：*Immunohistochemical detection of histone H3K27M mutation in pediatric midline gliomas*
**作者**：Bechet, D. et al.
**摘要**：作者验证了一种针对H3K27M突变蛋白的抗体(包括HIST3H3和H3F3A变体)在免疫组化中的应用，证实其高敏感性和特异性，成为临床诊断中线胶质瘤的重要工具。
3. **文献名称**：*Histone H3 mutations in pediatric brain tumors: molecular mechanisms and preclinical models*
**作者**：Sturm, D. et al.
**摘要**：本文综述了组蛋白H3突变(如HIST3H3和H3F3A的K27M)在儿童脑瘤中的致癌机制，并讨论了相关抗体的开发如何推动靶向治疗研究，强调抗体在机制研究中的关键作用。
---
这些文献聚焦于HIST3H3抗体在神经肿瘤领域的诊断应用及机制探索，尤其针对H3K27M突变检测。如需具体期刊信息或更多文献，可进一步补充关键词或研究场景。
The HIST3H3 antibody targets histone H3.3. a variant of the histone H3 family encoded by the *H3F3A* gene. Histones are core components of nucleosomes, playing critical roles in chromatin structure and epigenetic regulation. Unlike replication-dependent H3 isoforms, H3.3 is incorporated into chromatin in a replication-independent manner, often at transcriptionally active regions, and is associated with gene regulation, DNA repair, and chromatin remodeling.
Mutations in *H3F3A*, particularly the K27M and G34R/V substitutions, are hallmark alterations in certain cancers, such as pediatric high-grade gliomas (e.g., diffuse midline gliomas and giant cell glioblastomas). The HIST3H3 antibody is specifically designed to detect these oncogenic mutations, which drive tumorigenesis by altering histone post-translational modifications, disrupting chromatin architecture, and promoting dysregulated gene expression.
In research and diagnostics, HIST3H3 antibodies are vital tools for identifying H3.3 mutations via immunohistochemistry (IHC) or Western blot, aiding in tumor classification, prognosis assessment, and therapeutic stratification. Their specificity for mutant H3.3 helps distinguish these aggressive tumors from other CNS malignancies, guiding clinical management. Additionally, these antibodies support mechanistic studies exploring the role of H3.3 mutations in epigenetic dysregulation and potential therapeutic targets. Overall, HIST3H3 antibodies are essential in both translational neuro-oncology and basic chromatin biology research.
×
